Dr. John Cush RheumNow
2 years 8 months ago
Hemophagocytic Lymphohistiocytosis in Still's disease
Dr. Bella Mehta discusses abstract 1143, presented at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/8XvMsGtul2 https://t.co/HG0QOu5V77
Dr. John Cush RheumNow
2 years 8 months ago
FDA Warning on CAR-T Cell Therapy
The FDA issued a safety alert on CAR-T cell immunotherapies; noting reports of T-cell malignancies (CAR-positive lymphoma) arising in patients treated with BCMA- or CD19-directed autologous CAR T cell immunotherapies.
https://t.co/uxY7xgqgqn https://t.co/xyZrXXGGIy
Dr. John Cush RheumNow
2 years 8 months ago
Korean ULTRA registry studied 117 Gout pts starting ULT; compared T2T achievers (SUA< 6) vs non-achievers. @6 mos, 71% reached target SUA (w/ better adherence (98% vs. 76%) than non-achievers. T2T achievers assoc w/ good adherence, +FamHx, & HTN meds https://t.co/wTuvPqcan5 https://t.co/QD9j923sSa
Dr. John Cush RheumNow
2 years 8 months ago
Metanalysis shows the prevalence of self-reported sleep problems in #PsA ranged 30% to 85%. 6 studies showed poor sleep quality in 73% (statistically higher than controls 27%). Sleep ranked in the top 4 health-related quality of life domains by PsA pts. https://t.co/d79Ji3KCBu https://t.co/HJpqUIQ8x6
Dr. John Cush RheumNow
2 years 8 months ago
FINAL DAY for early bird pricing for RheumNow Live.
Take advantage of this discounted price TODAY!
https://t.co/UW9SMjEBYB https://t.co/DX2SJZYkUW
Dr. John Cush RheumNow
2 years 8 months ago
Maryland specialty clinic eval 1395 Lyme pts & saw marked differences between blacks & whites. Black patients had 5 fold (OR 4.93) higher risk of disseminated LD & delay in Abx Rx. Dissem Dz also more likely in men (OR, 1.6) EM Rash harder to spot https://t.co/Hhxr7hscaL https://t.co/J46JvHwRmc
Dr. John Cush RheumNow
2 years 8 months ago
Clinical Practice Res Database studied 51K gout pts before ULT therapy, 36% had ≥ 1 recurrent flares, 17% flared w/in 12 mos of Dx. Flares risk: Male, blacks, obese, CHF, CKD, CVD, diuretics, Hi SUA (HR 4.6). Only 28% Given ULT w/in 12 mos of Dx https://t.co/TAHBDxA6Th https://t.co/rwztpe7y2r
The American College of Rheumatology guidelines for the diagnosis and management of interstitial lung disease, which includes rheumatoid arthritis interstitial lung disease (RA-ILD), has been one of the most controversial topics in the runup to ACR Convergence.
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Two major reports on fatigue and fibromyalgia misfired, and "ankylosing spondylitis" is sent to the Rheumatology dead word cemetery.
Dr. John Cush RheumNow
2 years 8 months ago
QD Clinic - Eosinophilia in RA
High Eosinophil counts in Stable RA - what's the differential Dx?.
https://t.co/au606vNQob https://t.co/VJneBfGr4P
Men with axial spondyloarthritis (axSpA) were more likely than women to obtain substantial relief with tumor necrosis factor (TNF) inhibitors, a multinational study indicated.
Dr. John Cush RheumNow
2 years 8 months ago
ICYMI: Here at Last: Treatment Options for VEXAS
We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for nearly 3 years, but prior to #ACR23 there has been relatively little to say about how to treat it.
https://t.co/FnygxtDwx8 https://t.co/2j1nbsAAp0
